Weekly Digest – August 2025 Weekly Digest – August 2025 26 August 2025: Genmab receives FDA Breakthrough Therapy Designation for Rinatabart sesutecan (Rina-S) in advanced endometrial cancer (EC) The FDA granted Breakthrough Therapy Designation to Genmab’s rinatabart sesutecan (Rina-S) for […]
Weekly Digest – August 2025 Weekly Digest – August 2025 27 August 2025: HERTHENA-Breast04 Phase 3 trial of Patritumab deruxtecan initiated in patients with metastatic hormone receptor positive, HER2 negative breast cancer previously treated with endocrine therapy Daiichi Sankyo and […]
Weekly Digest – August 2025 Weekly Digest – August 2025 23 August 2025: Koas acquires antibody drug developer Novelty Nobility Koas, Korea’s top office furniture maker, announced a KRW 50 billion investment to acquire Novelty Nobility, making it a subsidiary […]
Weekly Digest – August 2025 Weekly Digest – August 2025 28 August 2025: Indena and TCG GreenChem join forces to advance next-generation ADC technologies Indena and TCG GreenChem formed a strategic partnership to accelerate payload–linker development for ADCs Indena contributes […]
Weekly Digest – August 2025 Weekly Digest – August 2025 18 August 2025: Ifinatamab deruxtecan granted Breakthrough Therapy Designation by U.S. FDA for patients with pretreated extensive stage small cell lung cancer The U.S. FDA has granted Breakthrough Therapy Designation […]
Weekly Digest – August 2025 Weekly Digest – August 2025 18 August 2025: Izalontamab brengitecan (EGFRxHER3 ADC) granted Breakthrough Therapy Designation by U.S. FDA for patients with previously treated advanced EGFR-mutated non-small cell lung cancer The U.S. FDA granted Breakthrough […]
Weekly Digest – August 2025 Weekly Digest – August 2025 19 August 2025: Antengene’s ATG-022 (CLDN18.2 ADC) granted Breakthrough Therapy Designation for the treatment of gastric/gastroesophageal junction adenocarcinoma Antengene’s CLDN18.2-targeting ADC ATG-022 received Breakthrough Therapy Designation from China’s NMPA for […]
Weekly Digest – August 2025 Weekly Digest – August 2025 19 August 2025: LM-302 (CLDN18.2 ADC), a class 1 new drug, has again been granted Breakthrough Therapy designation, demonstrating global advancement in research and development Lixin Pharmaceuticals LM-302 (CLDN18.2 ADC), […]
Weekly Digest – August 2025 Weekly Digest – August 2025 19 August 2025: Mabwell’s CDH17-targeting ADC 7MW4911 receives IND clearance from FDA Mabwell’s CDH17-targeting ADC 7MW4911 received FDA IND clearance to begin Phase 1/2 trials in advanced colorectal cancer and […]
Weekly Digest – August 2025 Weekly Digest – August 2025 19 August 2025: Henlius licenses Phase 3 innovative HER2 ADC from GeneQuantum Henlius has licensed exclusive development and commercialization rights for GeneQuantum’s HER2-targeted ADC GQ1005 in China and selected overseas […]
